This page shows the latest MDR-TB news and features for those working in and with pharma, biotech and healthcare.
aimed at eradicating diseases such as multidrug resistant tuberculosis (MDR-TB); and to create a level playing field between member states that will allow for a cooperative response to health threats. ... For example, the spread of MDR-TB within the EU
Typically, it occurs in patients who do not take their drugs as indicated by their doctor, and was first identified as a sub-category of MDR-TB in 2006. ... Around 9% of the 480, 000 MDR-TB cases estimated to have occurred in 2013 are thought to actually
nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the
The novel treatment for pulmonary multi‐drug resistant tuberculosis (MDR‐TB) is administered by directly observed therapy and indicated as part of combination therapy in adults with pulmonary MDR‐TB. ... MDR‐TB and preventing progression to more
According to the World Health Organization (WHO), there are about 170, 000 deaths globally each year due to MDR-TB. ... Both trials arms also received other therapies. Akihiko Otsuka, chairman of Otsuka, said that MDR-TB remained a “serious problem”
Multi drug-resistant TB (MDR-TB) is defined as resistance to the gold standard treatment of isoniazid and rifampicin. ... Bedaquiline has been approved for use as part of combination therapy, in adult patients with MDR-TB and has been shown to be active
More from news
Approximately 2 fully matching, plus 15 partially matching documents found.
No results were found
Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...